What is the recommended management for hypocalcemia?

Management of Hypocalcemia

Acute Symptomatic Hypocalcemia

For acute symptomatic hypocalcemia (tetany, seizures, cardiac arrhythmias, prolonged QT interval), immediately administer intravenous calcium chloride 10% solution, 10 mL (270 mg elemental calcium) over 2-5 minutes with continuous ECG monitoring. 1

Preferred Agent and Rationale

• Calcium chloride is superior to calcium gluconate for acute correction because 10 mL of 10% calcium chloride contains 270 mg elemental calcium versus only 90 mg in the same volume of calcium gluconate 1
• Administer slowly via a secure IV line while continuously monitoring ECG for arrhythmias, particularly bradycardia, hypotension, and cardiac arrest 1, 2
• If calcium chloride is unavailable, use calcium gluconate 10% solution 15-30 mL IV over 2-5 minutes as an alternative 1

Critical Safety Considerations During Acute Treatment

• Never administer calcium through the same line as sodium bicarbonate or phosphate-containing fluids due to precipitation risk 1, 2
• Exercise extreme caution when phosphate levels are elevated (>4.6 mg/dL) due to risk of calcium-phosphate precipitation in tissues 1
• In patients on cardiac glycosides (digoxin), calcium administration can cause synergistic arrhythmias; give slowly in small amounts with close ECG monitoring 2
• Avoid rapid administration to prevent hypotension, bradycardia, syncope, and cardiac arrest 2

Special Acute Scenarios

Hypomagnesemia with Hypocalcemia:

• Administer magnesium sulfate 1-2 g IV bolus first, then calcium replacement 1
• Hypomagnesemia causes hypocalcemia through impaired PTH secretion and end-organ PTH resistance; calcium supplementation alone will fail without correcting magnesium 1

Massive Transfusion/Trauma:

• Monitor ionized calcium levels closely during massive transfusion protocols 1
• Citrate in blood products binds calcium, and citrate metabolism is impaired by hypoperfusion, hypothermia, and hepatic insufficiency 1
• Early hypocalcemia correlates with the volume of colloids and blood products infused 1

Tumor Lysis Syndrome:

• Administer calcium gluconate 50-100 mg/kg IV slowly with ECG monitoring 1
• Use extreme caution when phosphate levels are high 1

---

Chronic Hypocalcemia Management

For chronic hypocalcemia, initiate daily oral calcium supplementation (calcium carbonate preferred) plus vitamin D, with total elemental calcium intake not exceeding 2,000 mg/day. 1, 3

Oral Calcium Supplementation

• Calcium carbonate is the preferred first-line agent due to highest elemental calcium content per dose and evidence-based efficacy 1
• Total elemental calcium from all sources (supplements + diet) should not exceed 2,000 mg/day 1
• If using calcium-based phosphate binders, limit elemental calcium from binders to ≤1,500 mg/day 1

Vitamin D Supplementation Strategy

• Correct vitamin D deficiency (25-OH vitamin D <30 ng/mL) with cholecalciferol or ergocalciferol first 1
• For hypoparathyroidism, initiate calcitriol 0.5 μg daily (or 20-30 ng/kg/day) or alfacalcidol 30-50 ng/kg/day 1, 3
• Active vitamin D metabolites (calcitriol) are reserved for severe or refractory cases, typically requiring endocrinologist consultation 3
• The combination of calcium and vitamin D is more effective than either agent alone 3

Target Calcium Levels

• Maintain serum calcium in the low-normal range (8.4-9.5 mg/dL) to minimize hypercalciuria and prevent nephrocalcinosis, renal calculi, and renal failure 1, 3
• In CKD stage 5, maintain calcium toward the lower end of normal range 1

Monitoring Requirements

• Measure serum calcium and phosphorus at least every 3 months during chronic treatment 1, 3
• Monitor pH-corrected ionized calcium (most accurate), magnesium, PTH, and creatinine regularly 1, 3
• Monitor for hypercalciuria to prevent nephrocalcinosis, especially when using active vitamin D 3
• Maintain calcium-phosphorus product <55 mg²/dL² to prevent metastatic calcification 1, 3

Adjusting Therapy

• Discontinue vitamin D if serum calcium exceeds 10.2 mg/dL to avoid hypercalcemia 3
• If serum phosphorus exceeds 4.6 mg/dL, add or increase phosphate binders before continuing vitamin D 3
• If secondary hyperparathyroidism develops, increase active vitamin D dose and/or decrease oral phosphate supplements 1

---

Post-Parathyroidectomy Hypocalcemia

Measure ionized calcium every 4-6 hours for the first 48-72 hours post-operatively, then twice daily until stable. 1

• If ionized calcium falls below 0.9 mmol/L, initiate calcium gluconate infusion at 1-2 mg elemental calcium/kg/hour 1
• Adjust infusion to maintain ionized calcium in normal range (1.15-1.36 mmol/L) 1
• When oral intake is possible, provide calcium carbonate 1-2 g three times daily plus calcitriol up to 2 mcg/day 1

---

Special Populations and Considerations

CKD and Dialysis Patients

• Recent paradigm shift away from permissive hypocalcemia due to risks of severe hypocalcemia (muscle spasms, paresthesias, myalgia) occurring in 7-9% of patients on calcimimetics 3
• Use individualized approach rather than routine correction in all CKD patients 1
• Adjust dialysate calcium concentration (standard 2.5 mEq/L; up to 3.5 mEq/L when calcium supply needed) 1
• Do not use calcium-based phosphate binders when: corrected calcium >10.2 mg/dL, PTH <150 pg/mL on 2 consecutive measurements, or severe vascular/soft tissue calcifications present 1

22q11.2 Deletion Syndrome

• 80% lifetime prevalence of hypocalcemia due to hypoparathyroidism, which may arise or recur at any age despite apparent childhood resolution 1, 3
• Daily calcium and vitamin D supplementation recommended universally 1, 3
• Avoid alcohol and carbonated beverages (especially colas) as they worsen hypocalcemia 1, 3
• Heightened surveillance during biological stress (surgery, childbirth, infection, fractures) 1, 3

Hypomagnesemia Correction

• Always check and correct magnesium levels as hypomagnesemia impairs PTH secretion and causes end-organ PTH resistance 1, 3
• Oral magnesium oxide 12-24 mmol daily is preferred for chronic supplementation 1

---

Critical Pitfalls to Avoid

• Overcorrection leading to iatrogenic hypercalcemia, renal calculi, and renal failure is a major risk with aggressive treatment 1, 3
• Extravasation of IV calcium causes tissue necrosis, ulceration, calcinosis cutis, and secondary infection; immediately discontinue infusion at that site if extravasation occurs 2
• Aluminum toxicity risk exists with calcium gluconate injection (up to 400 mcg/L aluminum), particularly concerning in renal impairment 2
• Dehydration can inadvertently cause overcorrection of hypocalcemia 3
• Changes in treatment compliance (particularly with calcitriol) can lead to unexpected hypercalcemia 3
• Symptoms may be confused with psychiatric conditions (anxiety, depression) 3

---

Monitoring During Vulnerable Periods

Targeted calcium monitoring is critical during: 1, 3

• Perioperative periods
• Pregnancy and perinatal period
• Acute illness or severe infection
• Puberty
• Surgery, fractures, or major injuries